Unknown

Dataset Information

0

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.


ABSTRACT: Accurate and sensitive detection of antibody to SARS-CoV-2 remains an essential component of the pandemic response. Measuring antibody that predicts neutralising activity and the vaccine response is an absolute requirement for laboratory-based confirmatory and reference activity. The viral receptor binding domain (RBD) constitutes the prime target antigen for neutralising antibody. A double antigen binding assay (DABA), providing the most sensitive format has been exploited in a novel hybrid manner employing a solid-phase S1 preferentially presenting RBD, coupled with a labelled RBD conjugate, used in a two-step sequential assay for detection and measurement of antibody to RBD (anti-RBD). This class and species neutral assay showed a specificity of 100 % on 825 pre COVID-19 samples and a potential sensitivity of 99.6 % on 276 recovery samples, predicting quantitatively the presence of neutralising antibody determined by pseudo-type neutralization and by plaque reduction. Anti-RBD is also measurable in ferrets immunised with ChadOx1 nCoV-19 vaccine and in humans immunised with both AstraZeneca and Pfizer vaccines. This assay detects anti-RBD at presentation with illness, demonstrates its elevation with disease severity, its sequel to asymptomatic infection and its persistence after the loss of antibody to the nucleoprotein (anti-NP). It also provides serological confirmation of prior infection and offers a secure measure for seroprevalence and studies of vaccine immunisation in human and animal populations. The hybrid DABA also displays the attributes necessary for the detection and quantification of anti-RBD to be used in clinical practice. An absence of detectable anti-RBD by this assay predicates the need for passive immune prophylaxis in at-risk patients.

SUBMITTER: Rosadas C 

PROVIDER: S-EPMC8782753 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.

Rosadas Carolina C   Khan Maryam M   Parker Eleanor E   Marchesin Federica F   Katsanovskaja Ksenia K   Sureda-Vives Macià M   Fernandez Natalia N   Randell Paul P   Harvey Ruth R   Lilley Alice A   Harris Benjamin H L BHL   Zuhair Mohamed M   Fertleman Michael M   Ijaz Samreen S   Dicks Steve S   Short Charlotte-Eve CE   Quinlan Rachael R   Taylor Graham P GP   Hu Kai K   McKay Paul P   Rosa Annachiara A   Roustan Chloe C   Zuckerman Mark M   El Bouzidi Kate K   Cooke Graham G   Flower Barnaby B   Moshe Maya M   Elliott Paul P   Spencer Alexandra J AJ   Lambe Teresa T   Gilbert Sarah C SC   Kingston Hugh H   Baillie J Kenneth JK   Openshaw Peter J M PJM   Semple Malcolm G MG   Cherepanov Peter P   McClure Myra O MO   Tedder Richard S RS  

Journal of virological methods 20220122


Accurate and sensitive detection of antibody to SARS-CoV-2 remains an essential component of the pandemic response. Measuring antibody that predicts neutralising activity and the vaccine response is an absolute requirement for laboratory-based confirmatory and reference activity. The viral receptor binding domain (RBD) constitutes the prime target antigen for neutralising antibody. A double antigen binding assay (DABA), providing the most sensitive format has been exploited in a novel hybrid man  ...[more]

Similar Datasets

| S-EPMC8595965 | biostudies-literature
| S-EPMC7498565 | biostudies-literature
| S-EPMC7774555 | biostudies-literature
| S-EPMC8372433 | biostudies-literature
| S-EPMC9442563 | biostudies-literature
| S-EPMC9860642 | biostudies-literature
| S-EPMC9957344 | biostudies-literature
| S-EPMC7744031 | biostudies-literature
| S-EPMC10580120 | biostudies-literature
| S-EPMC7589479 | biostudies-literature